What is the approximate market price of 0.01% atropine sulfate eye drops (EIKANCE)?

Regarding the price of 0.01% Atropine Sulfate Eye Drops (EIKANCE), the domestic original drug has not yet been launched, so there is no unified official selling price, and it is not included in the scope of medical insurance reimbursement. Overseas market data shows that the common specification of EIKANCE is 30 pieces of 0.01% 0.3ml, and the price per box is about more than 600 yuan. However, due to exchange rate changes, the actual price may fluctuate. On the other hand, there are already generic drugs on the market in some countries. For example, the 0.01% w/v*5ml version produced in India may be sold for tens of yuan per bottle, which is relatively more affordable. Although the ingredients of generic drugs are similar to those of brand-name drugs, there may be differences in stability, packaging and clinical use guidance. Therefore, you should be careful when choosing and purchase under the guidance of a doctor.

Long-term useControl of myopia with 0.01% atropine sulfate eye drops Parents need to consider the economic cost. The usage of one drop in each eye once a night means that the entire box of medicine needs to be consumed every month. The price of overseas original medicine is higher, so the pressure on family budget cannot be ignored. If original research drugs are launched in China and included in medical insurance in the future, it is expected to reduce long-term drug costs and benefit more children. Currently, for families who want to use the drug, it is recommended to purchase it through regular overseas drug purchase channels or import it under license, and strictly follow the doctor's prescription to avoid increased safety risks caused by purchasing drugs from unknown sources.

In addition to the price factor,The use value of 0.01% Atropine Sulfate Eye Drops is also reflected in its scientific basis. Multiple studies have shown that low-concentration atropine sulfate is safe and effective in controlling myopia in children, and is particularly effective in inhibiting axial growth. Combined with rational use of medication, regular review and scientific management, parents can provide their children with a continuous myopia prevention and control program if their finances allow, thereby reducing the risk of high myopia.

Reference materials:https://www.eikance.com.au/